Ma-Spore ALL 2020 Study

Inclusion Criteria:

1. Has been diagnosed with B-lineage ALL as evidenced by:
2. BMA blasts > 20% AND
3. Leukemic process in the bone marrow, peripheral blood or any extra medullarytissue with confirmation of B-lymphoid differentiation by flow immunophenotypingor histopathologically
4. Age < 41 years of age at enrolment
5. Written informed consent obtained from patient or legally acceptable representative (LAR)

Exclusion Criteria:

1. T-lineage ALL
2. Down syndrome with ALL
3. History of previous malignancies or this ALL is a second malignancy
4. Mixed phenotype acute leukemia (MPAL) or undifferentiated leukemia
5. Mature B-cell leukemia/lymphoma
6. Any previous cytotoxic therapy (chemotherapy/radiotherapy/immunotherapy). Patientpre-treated with short term steroid (< 7 days of duration within last 1 month prior toALL treatment start) may be enrolled after discussion and written approval from PI.These patients should be treated on at least intermediate arm.
7. Persistent renal dysfunction with creatinine more than upper limit of normal for agebefore start of induction therapy. Patients requiring temporary dialysis withoutpersistent renal dysfunction can qualify.
8. Liver dysfunction with direct bilirubin > 10x upper normal limit for age.
9. Any serious uncontrolled medical condition or impending end organ dysfunction thatwould impair the ability of the subject to receive protocol therapy
10. Doubtful compliance or ability to complete study therapy due to financial, social,familial or geographic reason, or in the judgement of site investigator